GSK Pipeline Update: 57 New Drug and Vaccine Candidates

GSK plc provided its Q1 2026 update on its drug development pipeline, emphasizing 57 potential new vaccines and medicines across various therapeutic areas. These candidates are progressing through different stages, from early-phase trials to registration.

The oncology and infectious disease portfolios show several advanced-stage assets. In Phase III/Registration, notable candidates include Lynavoy (linerixibat) for cholestatic pruritus, Benlysta (belimumab) for systemic sclerosis-associated interstitial lung disease, and the Arexvy vaccine for RSV prevention in older adults.

Further down the pipeline, GSK is advancing multiple candidates in Phase II trials. These include potential treatments for Alzheimer's disease, food allergies, and chronic Hepatitis B infection, alongside ongoing work in HIV, tuberculosis, and other infectious disease areas.

Early-stage development (Phase I) includes several programs targeting conditions such as chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and various cancers. Initial research also covers new vaccine technologies, including influenza and COVID-19, as well as efforts against malaria and urinary tract infections.

The company continues its commitment to a diverse research and development strategy, aiming to address significant unmet medical needs across its key therapeutic areas.